CLGN - CollPlant Biotechnologies Ltd. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

CLGN

COLLPLANT BIOTECHNOLOGIES LTD.

NASDAQ

$3.55

▲ UP 4.04% (0.14)

KEY STATISTICS

Market Cap$4.60 M

52w High$31.80

52w Low$2.64

Dividend Yield—

Frequency—

P/E-3.42

Volume236.15K

Shares Out.1.30M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Yehiel Tal

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 31, 2018

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$14.00

Target Low$11.00

Target Median$12.50

Target Consensus$12.50

UPCOMING EARNINGS

DateDec 2, 2026

DayWednesday

Rev. Est.$480.00K

DEC

WED

SPLIT RECORD

DATE	TYPE	RATIO
2026-09-04	Reverse	1:10
2016-12-01	Reverse	2:3

PRICE

$3.55 ▲ UP 4.04% (+$0.14)

OVERLAYS

About CollPlant Biotechnologies Ltd.

https://www.collplant.com ↗

CollPlant Biotechnologies, based in Israel, develops 3D bioprinting tissues, organs, and aesthetic products using plant-derived recombinant collagen, serving markets in the US, Canada, and Europe.

INDUSTRY

Biotechnology

A PRODUCT COLLPLANT BIOTECHNOLOGIES LTD. IS KNOWN FOR

Photocurable rhCollagen Dermal Filler

A next-generation injectable dermal filler made from plant-derived recombinant human collagen, designed for facial contouring and volume loss, currently in preclinical stages, with a focus on treating facial changes from rapid weight-loss via GLP-...